Prevalence, genetic drift of haemagglutinin, and antiviral resistance of influenza A/H3N2 viruses circulating in Shanghai in children during 2009-2012

Journal of Medical Virology

Volumn 86, Issue 6, 2014, Pages 1026-1033

  Cai, Jiehao ^a   Wang, Xiangshi ^a   Zhao, Baihui ^b   Yao, Weilei ^a   Wang, Xiaohong ^a   Zhu, Qirong ^a   Zeng, Mei ^a  

^a CHILDREN S HOSPITAL OF FUDAN UNIVERSITY   (China)

^b SHANGHAI MUNICIPAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Antiviral resistance; Hemagglutinin (HA); Influenza A H3N2 viruses; Shanghai

Indexed keywords

AMANTADINE; EPITOPE; HEMAGGLUTININ; INFLUENZA VACCINE; OSELTAMIVIR; ADAMANTANINE; ANTIVIRUS AGENT; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS RNA;

ANTIVIRAL RESISTANCE; ARTICLE; CHILD; CONTROLLED STUDY; EPIDEMIC; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC DRIFT; GENOTYPE; HUMAN; INFLUENZA A (H3N2); INFLUENZA VIRUS A H3N2; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTPATIENT; PHYLOGENY; PRESCHOOL CHILD; PREVALENCE; SCHOOL CHILD; SEQUENCE ANALYSIS; THROAT CULTURE; VIRUS DETECTION; ADOLESCENT; ANALOGS AND DERIVATIVES; CHINA; CLUSTER ANALYSIS; DNA SEQUENCE; DRUG EFFECTS; EPIDEMIOLOGY; GENETICS; INFANT; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MISSENSE MUTATION; NASOPHARYNX; NEWBORN; SEQUENCE HOMOLOGY; VIROLOGY;

ORTHOMYXOVIRIDAE;

ADOLESCENT; AMANTADINE; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CHINA; CLUSTER ANALYSIS; DRUG RESISTANCE, VIRAL; FEMALE; GENETIC DRIFT; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; MUTATION, MISSENSE; NASOPHARYNX; OSELTAMIVIR; PHYLOGENY; PREVALENCE; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY;

EID: 84897961907     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23854     Document Type: Article

References (36)

1. Ann J, Papenburg J, Bouhy X, Rheaume C, Hamelin ME, Boivin G. 2012. Molecular and antigenic evolution of human influenza A/H3N2 viruses in Quebec, Canada, 2009-2011. J Clin Virol 53:88-92.
2. Barr IG, McCauley J, Cox N, Daniels R, Engelhardt OG, Fukuda K, Grohmann G, Hay A, Kelso A, Klimov A, Odagiri T, Smith D, Russell C, Tashiro M, Webby R, Wood J, Ye Z, Zhang W. 2010. Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: Basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 Northern Hemisphere season. Vaccine 28:1156-1167.
3. Baz M, Abed Y, McDonald J, Boivin G. 2006. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 43:1555-1561.
4. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, Povinelli L, Cox NJ, Klimov AI. 2005. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern. Lancet 366:1175-1181.
5. Carr S, Ilyushina NA, Franks J, Adderson EE, Caniza M, Govorkova EA, Webster RG. 2011. Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer. Pediatr Infect Dis J 30:284-288.
6. Chinese National Influenza Center.(CNIC). 2009. Chinese Influenza Weekly Report (Week 48: Nov 30-Dec 6, 2009).
7. Deyde VM, Xu X, Bright RA, Shaw M, Smith CB, Zhang Y, Shu Y, Gubareva LV, Cox NJ, Klimov AI. 2007. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 196:249-257.
8. Deyde V, Garten R, Sheu T, Smith C, Myrick A, Barnes J, Xu X, Shaw M, Klimov A, Gubareva L. 2009. Genomic events underlying the changes in adamantane resistance among influenza A(H3N2) viruses during 2006-2008. Influenza Other Respir Viruses 3:297-314.
9. Dong H, Zhang Y, Xiong H, Yan A, Ding G, Chen Y, Xie L, Chen J, Zhang G, Hao P, Cong L, Lu Y, Che X, Wang X, Li Y, Yuen KY, Zhao G, Jin W. 2010. Detection of human novel influenza A (H1N1) viruses using multi-fluorescent real-time RT-PCR. Virus Res 147:85-90.
10. Esposito S, Molteni CG, Daleno C, Tagliabue C, Picciolli I, Scala A, Pelucchi C, Fossali E, Principi N. 2011. Impact of pandemic A/H1N1/2009 influenza on children and their families: Comparison with seasonal A/H1N1 and A/H3N2 influenza viruses. J Infect 63:300-307.
11. Ge Y, Cai J, Wang X, Yao W, Shen J, Zhu Q, Wang X, Zeng M. 2012. Childhood influenza in the outpatient setting in Shanghai, China. Pediatr Infect Dis J 31:e111-e116.
12. Hay AJ, Zambon MC, Wolstenholme AJ, Skehel JJ, Smith MH. 1986. Molecular basis of resistance of influenza A viruses to amantadine. J Antimicrob Chemother 18:19-29.
13. Huang JW, Yang JM. 2011. Changed epitopes drive the antigenic drift for influenza A (H3N2) viruses. BMC Bioinformatics 12:S31.
14. Lan Y, Zhang Y, Dong L, Wang D, Huang W, Xin L, Yang L, Zhao X, Li Z, Wang W, Li X, Xu C, Yang L, Guo J, Wang M, Peng Y, Gao Y, Guo Y, Wen L, Jiang T, Shu Y. 2010. A comprehensive surveillance of adamantane resistance among human influenza A virus isolated from mainland China between 1956 and 2009. Antivir Ther 15:853-859.
15. Laplante JM, Marshall SA, Shudt M, Van TT, Reisdorf ES, Mingle LA, Shult PA, St GK. 2009. Influenza antiviral resistance testing in new york and wisconsin, 2006 to 2008: Methodology and surveillance data. J Clin Microbiol 47:1372-1378.
16. Nelson MI, Simonsen L, Viboud C, Miller MA, Holmes EC. 2009. The origin and global emergence of adamantane resistant A/H3N2 influenza viruses. Virology 388:270-278.
17. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, Rode A, Kinnersley N, Ward P. 2000. Efficacy and safety of oseltamivir in treatment of acute influenza: A randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355:1845-1850.
18. Saito R, Li D, Shimomura C, Masaki H, Le MQ, Nguyen HL, Nguyen HT, Phan TV, Nguyen TT, Sato M, Suzuki Y, Suzuki H. 2006. An off-seasonal amantadine-resistant H3N2 influenza outbreak in Japan. Tohoku J Exp Med 210:21-27.
19. Salter A, Ni LB, Crowley B. 2011. Emergence and phylogenetic analysis of amantadine-resistant influenza A subtype H3N2 viruses in Dublin, Ireland, over six seasons from 2003/2004 to 2008/2009. Intervirology 54:305-315.
20. Samson M, Pizzorno A, Abed Y, Boivin G. 2013. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res 98:174-185.
21. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Butler EN, Wallis TR, Klimov AI, Gubareva LV. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 52:3284-3292.
22. Simonsen L, Viboud C, Grenfell BT, Dushoff J, Jennings L, Smit M, Macken C, Hata M, Gog J, Miller MA, Holmes EC. 2007. The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. Mol Biol Evol 24:1811-1820.
23. Stohr K. 2002. Influenza-WHO cares. Lancet Infect Dis 2:517.
24. Suzuki Y. 2011. Positive selection for gains of N-linked glycosylation sites in hemagglutinin during evolution of H3N2 human influenza A virus. Genes Genet Syst 86:287-294.
25. Tamura K, Dudley J, Nei M, Kumar S. 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24:1596-1599.
26. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. 1997. The CLUSTAL_X windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25:4876-4882.
27. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. 2004. Influenza-associated hospitalizations in the United States. JAMA 292:1333-1340.
28. Treanor J. 2004. Influenza vaccine-outmaneuvering antigenic shift and drift. N Engl J Med 350:218-220.
29. Westgeest KB, de Graaf M, Fourment M, Bestebroer TM, van Beek R, Spronken MI, de Jong JC, Rimmelzwaan GF, Russell CA, Osterhaus AD, Smith GJ, Smith DJ, Fouchier RA. 2012. Genetic evolution of the neuraminidase of influenza A (H3N2) viruses from 1968 to 2009 and its correspondence to haemagglutinin evolution. J Gen Virol 93:1996-2007.
30. Whitley RJ, Boucher CA, Lina B, Nguyen-Van-Tam JS, Osterhaus A, Schutten M, Monto AS. 2013. Global assessment of resistance to neuraminidase inhibitors: 2008-2011. The Influenza Resistance Information Study (IRIS). Clin Infect Dis 56:1197-1205.
31. World Health Organization (WHO). 2012. Influenza Centre London.February 2012 interim report. Report prepared for the WHO annual consultation on the composition of influenza vaccine for the Northern Hemisphere. 20th-22nd February 2012.
32. Wiley DC, Wilson IA, Skehel JJ. 1981. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289:373-378.
33. Wilson IA, Cox NJ. 1990. Structural basis of immune recognition of influenza virus hemagglutinin. Annu Rev Immunol 8:737-771.
34. Wingfield WL, Pollack D, Grunert RR. 1969. Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man. N Engl J Med 281:579-584.
35. Wu P, Goldstein E, Ho LM, Yang L, Nishiura H, Wu JT, Ip DK, Chuang SK, Tsang T, Cowling BJ. 2012. Excess mortality associated with influenza A and B virus in Hong Kong, 1998-2009. J Infect Dis 206:1862-1871.
36. Zaraket H, Saito R, Suzuki Y, Suzuki Y, Caperig-Dapat I, Dapat C, Shabana II, Baranovich T, Suzuki H. 2010. Genomic events contributing to the high prevalence of amantadine-resistant influenza A/H3N2. Antivir Ther 15:307-319.